• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OPKO Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    4/30/25 4:07:22 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPK alert in real time by email
    opk20250417_8k.htm
    false 0000944809 0000944809 2025-04-30 2025-04-30
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): April 30, 2025
     
    OPKO Health, Inc.
    (Exact Name of Registrant as Specified in its Charter)
     
    Delaware
     
    001-33528
     
    75-2402409
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
     
    4400 Biscayne Blvd.
    Miami,
    Florida
     
    33137
    (Address of Principal Executive Offices)
     
    (Zip Code)
    Registrant’s telephone number, including area code: (305) 575-4100
     
    Not Applicable
    Former name or former address, if changed since last report
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.01 per share
    OPK
    NASDAQ Global Select Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company         ☐         
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                  ☐
     


     
     

     
     
    ITEM 2.02.
    Results of Operations and Financial Condition.
     
    On April 30, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2025, as well as provide financial guidance. A copy of the press release is attached hereto as Exhibit 99.1.
     
    The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.
     
    ITEM 9.01.
    Financial Statements and Exhibits.
     
     
    (d)
    Exhibits
     
    Exhibit 
    No.
     
    Description
       
    99.1
     
    Press Release of the Company dated April 30, 2025
    104
      Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
       
    OPKO Health, Inc.
           
       
    By:
    /s/ Adam Logal
    Date: April 30, 2025
     
    Name:
    Adam Logal
       
    Title:
    Senior Vice President, Chief Financial Officer
           
     
     
    Get the next $OPK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPK

    DatePrice TargetRatingAnalyst
    4/25/2025Neutral
    Analyst
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    12/15/2022$3.00Buy
    H.C. Wainwright
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings